Compare USBC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USBC | ALDX |
|---|---|---|
| Founded | N/A | 2004 |
| Country | | United States |
| Employees | 6 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.2M | 293.0M |
| IPO Year | N/A | 2014 |
| Metric | USBC | ALDX |
|---|---|---|
| Price | $0.69 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | N/A | ★ 1.6M |
| Earning Date | N/A | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.14 |
| 52 Week High | N/A | $7.20 |
| Indicator | USBC | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 53.77 |
| Support Level | $0.68 | $4.98 |
| Resistance Level | $0.74 | $5.75 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 10.04 | 75.07 |
USBC Inc is a non-invasive medical diagnostics. The group is focused on the development and commercialization of proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Its Sensor technology elicits a dielectric response that is different for every molecule. The group considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology, with a first focus on non-invasively ascertaining blood glucose levels.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.